Endometrial safety during administration of the combined estrogen-progestogen hormone replacement drug Klimonorm (R) in perimenopausal women

The role of Klimonorm (R), a combined estrogen-progestogen hormonal replace ment drug, in the therapy of menstrual disorders and endometrial disease in the perimenopause was studied in 46 patients between 41-49 years of age wi th excessive or irregular menstrual bleeding. Treatment with Klimonorm (R) was started in women with benign endometrial changes and was continued for 12 months. Ultrasound evaluations of endometrial thickness were performed i n all patients a few days before the expected bleeding. Afterwards, a fract ionated dilatation and curettage was done and the specimens were evaluated. Control biopsies were performed after 6 and 12 months of therapy. Almost a ll patients treated with Klimonorm (R) experienced secretory transformation of the uterine lining. There were only a few hyperplastic specimens in dif ferent patients. A slight, insignificant reduction of endometrial thickness was observed. The duration of bleeding decreased significantly from 5.1 da ys at the beginning of the study, to 4.1 days after 3 months, and to 3.8 da ys after 6 months of treatment. Klimonorm (R) could be used safely and effe ctively for the treatment of perimenopausal endometrial abnormalities. (C) 2001 Prous Science. All rights reserved.